Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours

被引:0
|
作者
Pedro Marques
Sayka Barry
Eivind Carlsen
David Collier
Amy Ronaldson
Sherine Awad
Neil Dorward
Joan Grieve
Nigel Mendoza
Samiul Muquit
Ashley B. Grossman
Frances Balkwill
Márta Korbonits
机构
[1] Queen Mary University of London,Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry
[2] STHF,Department of Pathology
[3] The National Hospital for Neurology and Neurosurgery,Department of Neurosurgery
[4] UCLH,Department of Neurosurgery
[5] NHS Trust,Barts Cancer Institute, Barts and the London School of Medicine and Dentistry
[6] Charing Cross Hospital,undefined
[7] Imperial College,undefined
[8] Derriford Hospital,undefined
[9] Queen Mary University of London,undefined
关键词
Pituitary neuroendocrine tumour; Pituitary adenoma; Tumour microenvironment; Cytokine; Chemokine; Immune cell; Macrophages; Lymphocytes; Neutrophils; Epithelial-to-mesenchymal transition;
D O I
暂无
中图分类号
学科分类号
摘要
Non-tumoural cells within the tumour microenvironment (TME) influence tumour proliferation, invasiveness and angiogenesis. Little is known about TME in pituitary neuroendocrine tumours (PitNETs). We aimed to characterise the role of TME in the aggressive behaviour of PitNETs, focusing on immune cells and cytokines. The cytokine secretome of 16 clinically non-functioning PitNETs (NF-PitNETs) and 8 somatotropinomas was assessed in primary culture using an immunoassay panel with 42 cytokines. This was correlated with macrophage (CD68, HLA-DR, CD163), T-lymphocyte (CD8, CD4, FOXP3), B-lymphocyte (CD20), neutrophil (neutrophil elastase) and endothelial cells (CD31) content, compared to normal pituitaries (NPs, n = 5). In vitro tumour–macrophage interactions were assessed by conditioned medium (CM) of GH3 (pituitary tumour) and RAW264.7 (macrophage) cell lines on morphology, migration/invasion, epithelial-to-mesenchymal transition and cytokine secretion. IL-8, CCL2, CCL3, CCL4, CXCL10, CCL22 and CXCL1 are the main PitNET-derived cytokines. PitNETs with increased macrophage and neutrophil content had higher IL-8, CCL2, CCL3, CCL4 and CXCL1 levels. CD8+ T-lymphocytes were associated to higher CCL2, CCL4 and VEGF-A levels. PitNETs had more macrophages than NPs (p < 0.001), with a 3-fold increased CD163:HLA-DR macrophage ratio. PitNETs contained more CD4+ T-lymphocytes (p = 0.005), but fewer neutrophils (p = 0.047) with a 2-fold decreased CD8:CD4 ratio. NF-PitNETs secreted more cytokines and had 9 times more neutrophils than somatotropinomas (p = 0.002). PitNETs with higher Ki-67 had more FOXP3+ T cells, as well as lower CD68:FOXP3, CD8:CD4 and CD8:FOXP3 ratios. PitNETs with “deleterious immune phenotype” (CD68hiCD4hiFOXP3hiCD20hi) had a Ki-67 ≥ 3%. CD163:HLA-DR macrophage ratio was positively correlated with microvessel density (p = 0.015) and area (p < 0.001). GH3 cell-CM increased macrophage chemotaxis, while macrophage-CM changed morphology, invasion, epithelial-to-mesenchymal transition and secreted cytokines of GH3 cells. PitNETs are characterised by increased CD163:HLA-DR macrophage and reduced CD8:CD4 and CD8:FOXP3 T cell ratios. PitNET-derived chemokines facilitate macrophage, neutrophil and T cell recruitment into the tumours which can determine aggressive behaviour.
引用
收藏
相关论文
共 50 条
  • [41] Pituitary apoplexy as the first manifestation of non-functioning pituitary neuroendocrine tumour
    Dzialach, Lukasz
    Sobolewska, Joanna
    Respondek, Wioleta
    Wojciechowska-Luzniak, Agnieszka
    Witek, Przemyslaw
    ENDOKRYNOLOGIA POLSKA, 2024, 75 (01) : 111 - 112
  • [42] FLNA expression modulates pathological markers of pituitary neuroendocrine tumours
    Toledo, Jonathan
    Perez, Pablo Anibal
    Zanetti, Mical
    Diaz-Torga, Graciela
    Mukdsi, Jorge Humberto
    Gutierrez, Silvina
    JOURNAL OF ENDOCRINOLOGY, 2024, 260 (01)
  • [43] Goblet cell carcinoid tumours of the appendix: a unique neuroendocrine tumour
    Chetty, R.
    HISTOPATHOLOGY, 2008, 52 (06) : 770 - 771
  • [44] Immunohistochemical Analysis of Pituitary Neuroendocrine Tumours in a Tertiary Referral Centre
    Loughrey, P. B.
    Craig, S. G.
    Parkes, E. E.
    McArt, D. G.
    Hunter, S. J.
    James, J. A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 85 - 85
  • [45] Mapping of a novel tumour suppressor gene with a role in neuroendocrine tumours
    Pearce, SHS
    CLINICAL ENDOCRINOLOGY, 1999, 51 (01) : 19 - 20
  • [46] Tumour microenvironment: informing on minimal residual disease in solid tumours
    Klaus Pantel
    Catherine Alix-Panabières
    Nature Reviews Clinical Oncology, 2017, 14 : 325 - 326
  • [47] Differential proteomic expression in non-functional pituitary neuroendocrine tumours and pituitary glands
    Candy, Nicholas G.
    Ramezanpour, Mahnaz
    Bouras, George
    Chegeni, Nusha
    Chataway, Timothy
    Ormsby, Rebecca J.
    Jukes, Alistair K.
    Vreugde, Sarah
    Wormald, Peter-John
    Psaltis, Alkis J.
    RHINOLOGY, 2024, 62 (06) : 750 - 758
  • [48] Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours
    Cheng, Ya Qi
    Wang, Shou Bi
    Liu, Jia Hui
    Jin, Lin
    Liu, Ying
    Li, Chao Yang
    Su, Ya Ru
    Liu, Yu Run
    Sang, Xuan
    Wan, Qi
    Liu, Chang
    Yang, Liu
    Wang, Zhi Chong
    CELL PROLIFERATION, 2020, 53 (08)
  • [49] The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach
    Vela-Patino, Sandra
    Salazar, Ma. Isabel
    Taniguchi-Ponciano, Keiko
    Vadillo, Eduardo
    Gomez-Apo, Erick
    Escobar-Espana, Aurea
    Perez-Koldenkova, Vadim
    Bonifaz, Laura
    Aguilar-Flores, Cristina
    Marrero-Rodriguez, Daniel
    Mercado, Moises
    GENES, 2024, 15 (05)
  • [50] Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy
    Zhou, Yuhang
    Zhang, Anke
    Fang, Chaoyou
    Yuan, Ling
    Shao, Anwen
    Xu, Yuanzhi
    Zhou, Danyang
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (10) : 2744 - 2759